Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific personnel transactions rather than a financial performance report.
Material Changes
The filing discloses an increase in the notional allocation of GSK American Depositary Shares (ADSs) for a connected person. This change resulted from the revaluation of the cash element of a notional investment held within the GSK 401K plan on September 12, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is strictly a transaction notification.
Important Facts for Investors
- Transaction Date: September 12, 2014 (advised on September 15, 2014).
- Connected Person: Dr K Slaoui (Connected person of Dr M Slaoui).
- Transaction Type: Increase in notional allocation of ADSs.
- Quantity: 5 ADSs.
- Price: $47.06 per ADS.
- Context: The transaction occurred within the GSK 401K plan due to cash element revaluation.